The France-based gene therapy company Eyevensys SA has appointed Thierry Bordet as director of preclinical development to oversee its products for ophthalmic diseases. He joins Eyevensys from the Biotherapies Institute for Rare Diseases in Evry, France where he was responsible for the development of advanced therapy medicinal products including treatments for inherited retinitis pigmentosa.
Dr Bordet has a PhD in microbiology and virology from the Pierre & Marie Curie University Paris VI.
Eyevensys announced the appointment on 13 September 2017.
Copyright 2017 Evernow Publishing Ltd